Evaluation of CD133 and CD56/NCAM expression in Wilms tumor and their association with prognostic factors

Abstract

<em><strong>Objective(s):</strong></em> To validate certain markers for cancer stem cell populations and their clinical importance in Wilms tumor (WT)<br /><em><strong>Materials and Methods:</strong></em> Immunohistochemical study for CD133 and CD56/NCAM was performed on forty-six cases of WT that were diagnosed between 1999 and 2015, and the association of these markers with survival and prognostic factors was analyzed. <br /><em><strong>Results:</strong></em> Thirty-four (73.9%) of WTs were positive for CD133 and thirty-nine (84.8%) were positive for CD56/NCAM. A significant positive correlation between CD133 and CD56/NCAM expression and the National Wilms Tumor Stage (NWTS) and death was found. Moreover, overall survival time was significantly correlated with CD133 and CD56/NCAM H-score, NWTS stage, and death. <br /><em><strong>Conclusion:</strong></em> It seems that CD133 and CD56/NCAM expressions can be used as strong prognostic parameters for the survival of patients with WT and can be used to predict WT patients' stage. Moreover, their targeted therapies can abolish cancer stem cells in children with recurrent tumors.